This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Goldenberg, I. Search for Related Content PubMed Articles by Goldenberg, I.

Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia

An Extended Follow-Up of the BIP Trial

Ilan Goldenberg, MD^_*,, Michal Benderly, PhD, Uri Goldbourt, PhD^,,_* for the BIP Study Group

^_* Heart Institute, Sheba Medical Center, Tel Hashomer, Israel
Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

View larger version (9K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Usage of Nonstudy Lipid-Lowering Drugs by Treatment Group Kaplan-Meier estimates of the rate of usage of nonstudy lipid-lowering drugs during long-term follow-up by the original treatment allocation group.

View larger version (8K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Probability of Cardiac Death or Nonfatal MI by Treatment Group Kaplan-Meier estimates of the probability of the combined end point of cardiac death or nonfatal myocardial infarction (MI) by the original treatment allocation group.